Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
9
×
biotech
9
×
life sciences
national blog main
national top stories
9
×
boston blog main
national
boston top stories
clinical trials
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
europe blog main
fda
indiana blog main
indiana top stories
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
allergan
cancer
eli lilly
europe top stories
novartis
amgen
astrazeneca
glaxosmithkline
boehringer ingelheim
What
bio
roundup
fda
abbvie’s
acquisitions
cancer
ceo
daniel
day
days
debut
drug
gilead
ipo
labor
life
medicines
monday
moves
opioid
o’day
science
sciences
treatment
week
won
adults
ahead
alkermes
allergan
announced
antipsychotic
approved
august
barbecuing
benefits
biggest
biofourmis
biotech
black
Language
unset
9
×
Current search:
abbvie
×
unset
×
biotech
×
" national top stories "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More